The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: anti-respiratory syncytial virus (RSV) vaccines. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Innovation in pharma: anti-RSV vaccines

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multispecific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-RSV vaccines is a key innovation area in the pharmaceutical industry

Anti-RSV vaccines are vaccines that are designed to induce an immune response against respiratory syncytial virus (RSV), a common cause of respiratory tract infections in young children and the elderly. These vaccines typically use recombinant adenovirus or parapoxviruses to deliver RSV antigens to the body to stimulate an immune response.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-RSV vaccines.

Key players in anti-RSV vaccines – a disruptive innovation in the pharmaceutical industry

 ‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to anti-RSV vaccines

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
C. H. Boehringer Sohn 178 Unlock Company Profile
AstraZeneca 150 Unlock Company Profile
Merck 125 Unlock Company Profile
Centre National Research Scientific 106 Unlock Company Profile
Curevac 75 Unlock Company Profile
US Department of Health and Human Services 64 Unlock Company Profile
Cevante Animale 61 Unlock Company Profile
The United States Of America 54 Unlock Company Profile
GSK 43 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 43 Unlock Company Profile
Centre National de la Recherche Scientifique 43 Unlock Company Profile
Commonwealth Scientific and Industrial Research Organisation 42 Unlock Company Profile
Sanofi 38 Unlock Company Profile
Hookipa Pharma 34 Unlock Company Profile
Pfizer 27 Unlock Company Profile
Mitsubishi Chemical Group 26 Unlock Company Profile
Altimmune 24 Unlock Company Profile
Intervet 24 Unlock Company Profile
CSL 23 Unlock Company Profile
Novartis 23 Unlock Company Profile
Johnson & Johnson 22 Unlock Company Profile
Precigen 21 Unlock Company Profile
Theravectys 21 Unlock Company Profile
Panacea Biotec 21 Unlock Company Profile
BlueWillow Biologics 19 Unlock Company Profile
ViroNovative 19 Unlock Company Profile
AMVAC 18 Unlock Company Profile
Charles River Laboratories International 14 Unlock Company Profile
Najit Technologies 14 Unlock Company Profile
Corteva 13 Unlock Company Profile
The U.S. government 12 Unlock Company Profile
Stichting Wageningen Research 12 Unlock Company Profile
Codagenix 11 Unlock Company Profile
Zoetis 10 Unlock Company Profile
ioGenetics 10 Unlock Company Profile
Emergex Vaccines 10 Unlock Company Profile
Zydus Lifesciences 9 Unlock Company Profile
Fred Hutchinson Cancer Research Center 9 Unlock Company Profile
FDS Pharma 9 Unlock Company Profile
Henry M. Jackson Foundation for the Advancement of Military Medicine 9 Unlock Company Profile
aRigen Pharmaceuticals 9 Unlock Company Profile
Emergent BioSolutions 8 Unlock Company Profile
Viridos 8 Unlock Company Profile
Ceva Sante Animale 8 Unlock Company Profile
International AIDS Vaccine Initiative 8 Unlock Company Profile
Biomune 8 Unlock Company Profile
Takeda Pharmaceutical 8 Unlock Company Profile
The Henry M Jackson Foundation for the Advancement of Military Medicine 8 Unlock Company Profile
Japan Science and Technology Agency 8 Unlock Company Profile
Profectus BioSciences 8 Unlock Company Profile

Source: GlobalData Patent Analytics

C. H. Boehringer Sohn is one of the leading patent filers in Anti-RSV vaccines. The company has developed Bovalto Intranasal vaccine, which is being used for the immunization of cattle against the Parainfluenza 3 Virus. It has also filed several patents in this area for the development of a new variety of vaccines.

In terms of application diversity, Theravectys leads the pack, while ViroNovative  and ioGenetics stood in second and third positions, respectively. By means of geographic reach, Curevac held the top position, followed by GSK and Theravectys.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.